1-42 (21F12)

Clonality: monoclonal
Host: Unknown Host
Methods: IH, WB
Source: anti-amyloid beta 21F12
(Frederique Bard,
Elan Pharmaceuticals, So. San Francisco, CA
Johnson-Wood, et al, PNAS February 18, 1997)
Siderowf, 2010
Okereke, 2009
Serneels, 2009
Brody, 2008
Holmes, 2008
Shankar, 2008
Roberson, 2007
Salehi, 2006


immunogen = synthetic peptide fragment derived from different regions of amyloid-beta and coupled to a carrier protein


amyloid-beta; recognizes amino acids 33-42; negligible crossreactivity (1–40

Comments / Questions

No Available Comments

Make a comment or submit a question

To make a comment you must login or register.


Paper Citations

  1. . CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010 Sep 21;75(12):1055-61. PubMed.
  2. . Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol. 2009 Oct;66(10):1247-53. PubMed.
  3. . gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science. 2009 May 1;324(5927):639-42. Epub 2009 Mar 19 PubMed.
  4. . Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008 Aug 29;321(5893):1221-4. PubMed.
  5. . Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 Jul 19;372(9634):216-23. PubMed.
  6. . Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 Aug;14(8):837-42. PubMed.
  7. . Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007 May 4;316(5825):750-4. PubMed.
  8. . Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006 Jul 6;51(1):29-42. PubMed.

Other Citations

  1. Frederique Bard

External Citations

  1. Paper

Further Reading